Suppr超能文献

朗格汉斯细胞异常的趋化因子受体表达及趋化因子产生是朗格汉斯细胞组织细胞增生症发病机制的基础。

Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis.

作者信息

Annels Nicola E, Da Costa Cristiana E T, Prins Frans A, Willemze Annemieke, Hogendoorn Pancras C W, Egeler R Maarten

机构信息

Leiden University Medical Center, Department of Pediatrics, Division of Immunology, Hematology, Oncology, BMT and Autoimmune Diseases, PO Box 9600, 2300 RC Leiden, Netherlands.

出版信息

J Exp Med. 2003 May 19;197(10):1385-90. doi: 10.1084/jem.20030137. Epub 2003 May 12.

Abstract

Langerhans cell histiocytosis (LCH) is characterized by a clonal proliferation and retention of cells with a Langerhans cell (LC)-like phenotype at various sites within the body. The present study set out to elucidate whether aberrant expression of chemokine receptors or dysregulation of chemokine production in LCH lesions could explain abnormal retention of these cells. Immunohistochemical analysis on 13 LCH biopsies of bone, skin, and lymph node all expressed the immature dendritic cell (DC) marker CCR6 on the lesional LCs and absence of the mature DC marker CCR7. Furthermore, regardless of the tissue site, LCH lesions markedly overexpressed CCL20/MIP-3alpha, the ligand for CCR6. The lesional LCs appeared to be the source of this CCL20/MIP-3alpha production as well as other inflammatory chemokines such as CCL5/RANTES and CXCL11/I-TAC. These may explain the recruitment of eosinophils and CD4+CD45RO+ T cells commonly found in LCH lesions. The findings of this study emphasize that, despite abundant TNF-alpha, lesional LCs remain in an immature state and are induced to produce chemokines, which via autocrine and paracrine mechanisms cause not only the retention of the lesional LCs but also the recruitment and retention of other lesional cells. We postulate that the lesional LCs themselves control the persistence and progression of LCH.

摘要

朗格汉斯细胞组织细胞增多症(LCH)的特征是具有朗格汉斯细胞(LC)样表型的细胞在体内多个部位发生克隆性增殖并滞留。本研究旨在阐明LCH病变中趋化因子受体的异常表达或趋化因子产生的失调是否可以解释这些细胞的异常滞留。对13例骨、皮肤和淋巴结的LCH活检标本进行免疫组织化学分析,结果显示病变的LC均表达未成熟树突状细胞(DC)标志物CCR6,而缺乏成熟DC标志物CCR7。此外,无论组织部位如何,LCH病变均显著过表达CCR6的配体CCL20/MIP-3α。病变的LC似乎是CCL20/MIP-3α以及其他炎症趋化因子如CCL5/RANTES和CXCL11/I-TAC产生的来源。这些可能解释了LCH病变中常见的嗜酸性粒细胞和CD4+CD45RO+T细胞的募集。本研究结果强调,尽管有大量肿瘤坏死因子-α,但病变的LC仍处于未成熟状态,并被诱导产生趋化因子,这些趋化因子通过自分泌和旁分泌机制不仅导致病变的LC滞留,还导致其他病变细胞的募集和滞留。我们推测病变的LC自身控制着LCH的持续存在和进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1a6/2193776/edc4e8d87ec8/20030137f1.jpg

相似文献

6
Langerhans cell histiocytosis: a cytokine/chemokine-mediated disorder?
Eur Cytokine Netw. 2011 Sep;22(3):148-53. doi: 10.1684/ecn.2011.0290.
7
Langerhans-cell histiocytosis 'insight into DC biology'.
Trends Immunol. 2003 Apr;24(4):190-6. doi: 10.1016/s1471-4906(03)00063-2.

引用本文的文献

1
Langerhans Cell Histiocytosis and Other Histiocytic Lesions.
Head Neck Pathol. 2025 Feb 25;19(1):26. doi: 10.1007/s12105-025-01766-2.
3
Langerhans cell histiocytosis: current advances in molecular pathogenesis.
Front Immunol. 2023 Oct 26;14:1275085. doi: 10.3389/fimmu.2023.1275085. eCollection 2023.
6
Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis.
Cancer Sci. 2023 May;114(5):1871-1881. doi: 10.1111/cas.15758. Epub 2023 Feb 27.
7
Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.
Cell Commun Signal. 2022 Dec 19;20(1):195. doi: 10.1186/s12964-022-00917-0.
8
Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis.
Front Oncol. 2022 Jan 21;11:780191. doi: 10.3389/fonc.2021.780191. eCollection 2021.
9
[Giant cell tumor of bone : Morphology, molecular pathogenesis, and differential diagnosis].
Pathologe. 2020 Mar;41(2):134-142. doi: 10.1007/s00292-020-00760-5.

本文引用的文献

1
Expression of cell cycle-related gene products in Langerhans cell histiocytosis.
J Pediatr Hematol Oncol. 2002 Dec;24(9):727-32. doi: 10.1097/00043426-200212000-00009.
2
Induction of macrophage-inflammatory protein-3alpha gene expression by TNF-dependent NF-kappaB activation.
J Immunol. 2002 Jun 1;168(11):5621-8. doi: 10.4049/jimmunol.168.11.5621.
5
Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo.
Eur J Immunol. 2001 Mar;31(3):812-22. doi: 10.1002/1521-4141(200103)31:3<812::aid-immu812>3.0.co;2-l.
6
Differentiation of Langerhans cells in Langerhans cell histiocytosis.
Blood. 2001 Mar 1;97(5):1241-8. doi: 10.1182/blood.v97.5.1241.
7
Dendritic cell biology and regulation of dendritic cell trafficking by chemokines.
Springer Semin Immunopathol. 2000;22(4):345-69. doi: 10.1007/s002810000053.
8
Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions.
Eur J Cancer. 2000 Oct;36(16):2105-10. doi: 10.1016/s0959-8049(00)00296-3.
9
Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization.
Br J Dermatol. 2000 Mar;142(3):401-12. doi: 10.1046/j.1365-2133.2000.03349.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验